Project Grant R21CA296216
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$376K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
The National Cancer Institute (NCI) awarded a $1,905,304 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Washington University in St. Louis to conduct research on "Accelerated Brachytherapy Forward Chemoradiation Therapy (ABC-RT) for Cervical Cancer". The 5-year project, starting August 2024, aims to determine if an accelerated brachytherapy-forward chemoradiation therapy approach can safely shorten treatment time and maximize the anti-tumor immune response...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Osel, Inc., a biotechnology company based in Mountain View, California, to develop a novel antimicrobial approach to treat chemoradiation-resistant cervical cancer. The key products and services to be delivered under this $295,881 award, which runs from May 2025 to April 2026, are: Synthesis and characterization of a selective bacteriocin inhibitor, GASK7B, that can...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a short RNA therapeutic to treat ovarian cancer at Nuago Therapeutics Inc. in Chicago, IL. The award will fund research to create a novel, targeted therapy that aims to induce DNA damage in ovarian cancer cells. This project, running from June 2025 through May 2026, seeks to advance a potential new treatment approach that could improve outcomes for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $112,052 to The Trustees of the University of Pennsylvania to conduct research aimed at overcoming treatment resistance in gynecological cancers. The key products and services to be delivered include: Testing new therapies that exploit survival pathways critical for cancers with CCNE1 amplification, which are often platinum-resistant. This includes evaluating biomarkers beyond...
This $530,697 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pennsylvania to investigate the use of protein arginine methyltransferase (PRMT) inhibitors for treating high-grade serous ovarian cancer and triple-negative breast cancer. The key objectives are to: 1) characterize the molecular mechanisms of PRMT inhibitor mono- and combination therapies, 2) evaluate the therapeutic potential of PRMT inhibitors in...
This federal Project Grant award of $412,429 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate novel approaches to overcome drug resistance in high-grade serous ovarian cancer (HGSOC). The award aims to demonstrate that combining the drug clofarabine with either a PARP inhibitor or an ATR inhibitor can sensitize CCNE1-driven tumors to these therapies by inducing replication stress through nuclear translocation of the protein cathepsin...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $800,888 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to evaluate a combination therapy approach for treating platinum resistant ovarian cancer. The project aims to assess the safety and tolerability of combining the CLK/DYRK inhibitor Cirtuvivint with the PARP inhibitor Olaparib in patients with BRCA/HRD deficiencies. The research...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico Health Sciences Center (UNM HSC) to conduct research on the mechanisms of papillomavirus tumor regression induced by MEK signaling inhibition. The 5-year project aims to understand how MEK inhibition reduces expression of the HPV oncogenes E6 and E7, leading to diminished keratinocyte proliferation and activation of innate immune responses to...
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...